RU2011150619A - Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения - Google Patents
Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения Download PDFInfo
- Publication number
- RU2011150619A RU2011150619A RU2011150619/02A RU2011150619A RU2011150619A RU 2011150619 A RU2011150619 A RU 2011150619A RU 2011150619/02 A RU2011150619/02 A RU 2011150619/02A RU 2011150619 A RU2011150619 A RU 2011150619A RU 2011150619 A RU2011150619 A RU 2011150619A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- proliferative disease
- compound
- pharmaceutically acceptable
- phosphoinositide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 13
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title claims 4
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title claims 4
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 claims abstract 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 16
- 230000002062 proliferating effect Effects 0.000 claims abstract 16
- 102000038030 PI3Ks Human genes 0.000 claims abstract 6
- 108091007960 PI3Ks Proteins 0.000 claims abstract 6
- 239000003623 enhancer Substances 0.000 claims abstract 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract 5
- 239000008280 blood Substances 0.000 claims abstract 5
- 210000004369 blood Anatomy 0.000 claims abstract 5
- 239000003937 drug carrier Substances 0.000 claims abstract 5
- 239000008103 glucose Substances 0.000 claims abstract 5
- 230000005764 inhibitory process Effects 0.000 claims abstract 5
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 5
- 230000037361 pathway Effects 0.000 claims abstract 5
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 claims abstract 4
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 claims abstract 4
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract 4
- 206010006187 Breast cancer Diseases 0.000 claims abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 3
- 102000004877 Insulin Human genes 0.000 claims abstract 3
- 108090001061 Insulin Proteins 0.000 claims abstract 3
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 3
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- 229940125396 insulin Drugs 0.000 claims abstract 3
- 208000037841 lung tumor Diseases 0.000 claims abstract 3
- 230000035772 mutation Effects 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 230000035945 sensitivity Effects 0.000 claims abstract 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 6
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims 2
- BMMXYEBLEBULND-UHFFFAOYSA-N BGT226 free base Chemical compound C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 BMMXYEBLEBULND-UHFFFAOYSA-N 0.000 claims 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 2
- 229940123208 Biguanide Drugs 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 claims 2
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09160440.5 | 2009-05-15 | ||
| EP09160440 | 2009-05-15 | ||
| PCT/EP2010/056538 WO2010130779A2 (en) | 2009-05-15 | 2010-05-12 | COMBINATION OF A PBOSPBOINOSITKLE 3-KSπASE INHIBITOR AND AN ANTIDIABETIC COMPOUND |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011150619A true RU2011150619A (ru) | 2013-06-20 |
Family
ID=40983590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011150619/02A RU2011150619A (ru) | 2009-05-15 | 2010-05-12 | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120059005A1 (enExample) |
| EP (1) | EP2429516A2 (enExample) |
| JP (1) | JP2012526772A (enExample) |
| KR (1) | KR20120096869A (enExample) |
| CN (1) | CN102958518A (enExample) |
| AU (1) | AU2010247397B2 (enExample) |
| BR (1) | BRPI1010979A2 (enExample) |
| CA (1) | CA2760179A1 (enExample) |
| MX (1) | MX2011012201A (enExample) |
| RU (1) | RU2011150619A (enExample) |
| WO (1) | WO2010130779A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| EP2621908A2 (en) * | 2010-10-01 | 2013-08-07 | Novartis AG | Manufacturing process for pyrimidine derivatives |
| HK1220900A1 (zh) | 2013-04-12 | 2017-05-19 | Ned Biosystems, Inc. | 癌症的治疗 |
| US11319376B2 (en) | 2016-08-03 | 2022-05-03 | Remd Biotherapeutics, Inc. | Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer |
| CA3102279A1 (en) * | 2018-06-01 | 2019-12-05 | Cornell University | Combination therapy for pi3k-associated disease or disorder |
| AU2019310335A1 (en) * | 2018-07-23 | 2021-02-11 | F. Hoffmann-La Roche Ag | Methods of treating cancer with PI3K inhibitor, GDC-0077 |
| WO2020076432A1 (en) * | 2018-10-08 | 2020-04-16 | Genentech, Inc. | Methods of treating cancer with pi3k alpha inhibitors and metformin |
| CA3165479A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| CN120361228B (zh) * | 2025-04-08 | 2025-11-21 | 复旦大学附属妇产科医院 | 一种葡萄糖激酶激活剂与pi3k抑制剂的组合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004066929A2 (en) * | 2003-01-24 | 2004-08-12 | Bristol-Myers Squibb Company | Cycloalkyl containing anilide ligands for the thyroid receptor |
| JP5371426B2 (ja) * | 2004-07-09 | 2013-12-18 | プロルックス ファーマシューティカルズ コープ． | ワートマニン類似体及び化学療法薬と組み合わせた同一物を使用する方法 |
| US7714005B2 (en) * | 2004-12-22 | 2010-05-11 | The Ohio State University Research Foundation | Small molecule Bcl-xL/Bcl-2 binding inhibitors |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| TW200824678A (en) * | 2006-08-11 | 2008-06-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| AU2007334343A1 (en) * | 2006-12-15 | 2008-06-26 | Ordway Research Institute, Inc. | Treatments of therapy-resistant diseases comprising drug combinations |
| US20100272717A1 (en) * | 2007-12-13 | 2010-10-28 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| WO2009155659A1 (en) * | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
| CN102089007B (zh) * | 2008-07-11 | 2013-05-15 | 诺瓦提斯公司 | (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品 |
-
2010
- 2010-05-12 MX MX2011012201A patent/MX2011012201A/es not_active Application Discontinuation
- 2010-05-12 RU RU2011150619/02A patent/RU2011150619A/ru not_active Application Discontinuation
- 2010-05-12 BR BRPI1010979A patent/BRPI1010979A2/pt not_active IP Right Cessation
- 2010-05-12 US US13/319,536 patent/US20120059005A1/en not_active Abandoned
- 2010-05-12 CA CA2760179A patent/CA2760179A1/en not_active Abandoned
- 2010-05-12 KR KR1020117027030A patent/KR20120096869A/ko not_active Withdrawn
- 2010-05-12 JP JP2012510289A patent/JP2012526772A/ja active Pending
- 2010-05-12 WO PCT/EP2010/056538 patent/WO2010130779A2/en not_active Ceased
- 2010-05-12 AU AU2010247397A patent/AU2010247397B2/en not_active Ceased
- 2010-05-12 CN CN2010800199053A patent/CN102958518A/zh active Pending
- 2010-05-12 EP EP10718226A patent/EP2429516A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010130779A3 (en) | 2013-03-28 |
| CA2760179A1 (en) | 2010-11-18 |
| AU2010247397A1 (en) | 2011-11-03 |
| EP2429516A2 (en) | 2012-03-21 |
| JP2012526772A (ja) | 2012-11-01 |
| US20120059005A1 (en) | 2012-03-08 |
| AU2010247397B2 (en) | 2012-07-12 |
| KR20120096869A (ko) | 2012-08-31 |
| MX2011012201A (es) | 2011-12-08 |
| WO2010130779A2 (en) | 2010-11-18 |
| CN102958518A (zh) | 2013-03-06 |
| BRPI1010979A2 (pt) | 2018-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
| EP2320903B1 (en) | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT | |
| JP7288482B2 (ja) | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 | |
| KR101673731B1 (ko) | 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법 | |
| US20230202981A1 (en) | Novel small molecules for targeted degradation of untargetable kras in cancer therapy | |
| CN105338977B (zh) | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 | |
| JP2022088616A (ja) | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 | |
| JP2019511526A5 (enExample) | ||
| JP2020512977A (ja) | Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ | |
| US20190290652A1 (en) | Method for treatment of solid malignancies including advanced or metastatic solid malignancies | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| JP2012526772A5 (enExample) | ||
| CN107427522A (zh) | 用于治疗黑素瘤的阿吡莫德 | |
| JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
| TW201244716A (en) | Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor | |
| NZ608375A (en) | Pharmaceutical combination of an mtor catalytic inhibitor and an allosteric mtor inhibitor | |
| KR20200128510A (ko) | 림프성 악성종양을 치료하는 방법 | |
| WO2016193955A1 (en) | Combinations of kinase inhibitors for treating colorectal cancer | |
| NZ580867A (en) | Method of treating melanoma | |
| CN101346137B (zh) | 含有孔布勒塔斯塔坦与抗癌剂的组合物 | |
| EP2313097B1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents | |
| JP2006518355A (ja) | インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140903 |